Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – The Jakarta Post – Jakarta Post
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
Noosa News23 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General21 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Business23 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000
-
Noosa News23 hours agoGrow it local | Noosa Today